Relypsa, Inc. Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting
5/23/2011 7:15:37 AM
Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company’s lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels). These data were presented in a poster titled “A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for the Potassium Binding Polymer RLY5016 in Patients with Heart Failure and Chronic Kidney Disease” (Poster PO-127) at the American Society of Hypertension Annual Meeting in New York.